Vedolizumab (Entyvio)

This medication is used to treat CROHN’S DISEASE and ULCERATIVE COLITIS

Included in a drug class called integrin receptor antagonists

Works by reducing inflammation that leads to the symptoms of Crohn’s / ulcerative colitis

DRUG ADMINISTRATION
- Intravenous (IV) infusion given by a healthcare professional
- Frequency of administration as prescribed by your provider

POSSIBLE SIDE EFFECTS INCLUDE, BUT ARE NOT LIMITED TO:
- Rare risk of anti-drug antibody formation
- Rare risk of infusion reaction
- Unclear risk of increased upper respiratory viruses (colds) and joint pains

These rare risks are outweighed by potential complications of untreated inflammatory bowel disease

ADDITIONAL TESTING AND MONITORING
Prior to starting this medication, your doctor may order:
- Blood counts and liver tests
- Tests for inflammation (blood and/or stool test)
- Stool tests to rule out infection
- Abdominal imaging and/or colonoscopy

While on this medication, your doctor may order:
- Blood counts and liver tests regularly to ensure safety
- Repeat tests for inflammation and abdominal imaging and/or colonoscopy to assess response to treatment

OTHER IMPORTANT INFORMATION
- This medication is safe to use in pregnancy and breastfeeding
- Make sure you are up to date on your vaccinations including: annual flu vaccine, Pneumovax, Prevnar-13, tetanus, hepatitis A and B, and Shingrix (age >50)
- Avoid LIVE vaccines while on this medication
- Financial assistance may be available
- This medication should be taken exactly as prescribed to properly treat the disease
- Please contact your provider if you notice any signs or symptoms of infection
- Do not stop or hold this medication without contacting your gastroenterologist

Beth Israel Deaconess Medical Center
617-754-8888

Lahey Hospital & Medical Center
781-744-8740